Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Validation of SATURN; an Inexpensive, Freely-available, and Fully Self-administered Cognitive Screening Test.
Aging, Dementia, and Behavioral Neurology
P15 - Poster Session 15 (12:00 PM-1:00 PM)
10-011
To develop and validate a free, public domain, automatically scored, and self-administered cognitive screening test.
Cognitive screening tests improve detection of dementia in the outpatient setting, and are helpful in select inpatient settings. Barriers to widespread screening include provider time investment and training (for test administration and scoring). We therefore developed Self-Administered Tasks Uncovering Risk of Neurodegeneration (SATURN) for inexpensive (<$100) computer tablets.
SATURN is a thirty-point test including orientation, word recall, and math items adapted from the Saint Louis University Mental Status test, modified versions of the Stroop and Trails tasks, and other assessments of visuospatial function and memory. We recruited English-speaking neurology clinic patients and their partners aged 50-89 years. After taking SATURN and the Montreal Cognitive Assessment (MoCA), participants answered a brief survey including demographics and test preferences. For patients recruited from dementia clinics (n=17), clinical status was quantified with the clinical dementia rating scale (CDR), and compared to SATURN and MoCA scores (for care partners, CDR=0). SATURN and the MoCA were also compared to one-another.
Twenty-four patient-partner dyads (n=47) were recruited. Four patients with moderate-to-severe dementia (CDRglobal ≥ 2.0) were not scorable based on pre-defined reading proficiency criteria. For the remaining (n=43) participants, (52% women; age (mean±sd) 65.9±9.8 years) SATURN and MoCA scores were highly correlated (r=0.90; p<0.001), and similarly associated with clinical status (for ANOVA vs CDRglobal, SATURN F[34,1]=82.8, MoCA F[34,1]=94.5; for Spearman’s rank correlation vs CDRsum-of-boxes, SATURN rho=-0.79, MoCA rho=-0.82; all p<0.001). Most participants (86%) reported SATURN was easy to use, and many either preferred SATURN over the MoCA (49%) or felt the same about both (30%).

SATURN is a freely available (https://doi.org/10.5061/dryad.02v6wwpzr) and fully self-administered cognitive screening test. Since it performs well compared to CDR ratings and MoCA scores in patients who can read, it may enjoy widespread use.

Authors/Disclosures
David P. Bissig, MD (UC Davis Neurology)
PRESENTER 		Dr. Bissig has received personal compensation in the range of $100,000-$499,999 for serving as a Physician with University of California - Davis.
Deniz Erten-Lyons, MD, FÂ鶹´«Ã½Ó³»­ (FDA) Dr. Erten-Lyons has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acadia Pharamceuticals.
Helmi L. Lutsep, MD, FÂ鶹´«Ã½Ó³»­ (Oregon Health & Science University) Dr. Lutsep has received personal compensation in the range of $0-$499 for serving as a Consultant for Abbott. Dr. Lutsep has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Lutsep has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Coherex Medical. Dr. Lutsep has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/Mayo Cinic. Dr. Lutsep has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medscape Neurology.
Jeffrey A. Kaye, MD, FÂ鶹´«Ã½Ó³»­ (Oregon Hlth Sci Univ.) Dr. Kaye has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Kaye has stock in Life Analytics. The institution of Dr. Kaye has received research support from NIH. The institution of Dr. Kaye has received research support from NSF. The institution of Dr. Kaye has received research support from AbbVie. Dr. Kaye has received intellectual property interests from a discovery or technology relating to health care.